RegulatoryCompany release

Elutia to file antibiotic-coated NXT-41x with FDA in Q4 after rabbit study

🇺🇸 Elutia Inc. (ELUT) · Thu 05 Nov 2026

Elutia says a GLP rabbit study of its antibiotic-coated biologic matrix met its endpoints, with no viable MRSA or E. coli recovered, and it plans a Q4 2026 FDA submission.

Elutia reported third-quarter 2026 results on 5 November, saying a GLP rabbit study of NXT-41x met its endpoints. The product is an antibiotic-coated biologic matrix intended for reconstructive and breast surgery. According to the company, no viable MRSA or E. coli was recovered in the study.

Elutia plans to submit NXT-41x to the US Food and Drug Administration in the fourth quarter of 2026 and is targeting clearance in the first half of 2027. It also expects an FDA decision this quarter on NXT-41, the drug-free version of the matrix.

On financing, the company said it raised $26 million without issuing equity. The funds came from a loan, a business sale and an escrow release. Cardiovascular sales rose 20% to $1.1 million.

The source material was limited to the company's summary of its results, so details of the study design, the regulatory pathway for NXT-41x and the terms of the financing are not available.

What it means for your team

  • Regulatory teams tracking combination or antibiotic-coated implantable products should watch for the NXT-41x submission, planned for Q4 2026, and for the FDA decision on NXT-41 expected this quarter.
  • The study result is company-reported; the full data and the FDA's view of the pre-clinical package are not yet public.
  • Clearance for NXT-41x is targeted for the first half of 2027, a timetable that depends on FDA review.

Company's press release (SEC filing): Elutia Inc. ↗

Article written by VigiEye from the official source (Elutia Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →